Compare · ABBV vs ROIV
ABBV vs ROIV
Side-by-side comparison of AbbVie Inc. (ABBV) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $453.12B, about 18.1x ROIV ($25.02B).
- Over the past year, ABBV is up 21.1% and ROIV is up 179.7% - ROIV leads by 158.6 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- ABBV has more recent analyst coverage (25 ratings vs 18 for ROIV).
- Company
- AbbVie Inc.
- Roivant Sciences Ltd.
- Price
- $256.50+0.37%
- $34.60-0.32%
- Market cap
- $453.12B
- $25.02B
- 1M return
- +2.24%
- +2.05%
- 1Y return
- +21.07%
- +179.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 18
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ABBV
- AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
- AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
Latest ROIV
- Roivant Sciences Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Roivant Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
- Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
- JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
- CFO Pulik Richard covered exercise/tax liability with 5,749 shares, decreasing direct ownership by 2% to 271,810 units (SEC Form 4) (withholding obligation)
- President & Immunovant CEO Venker Eric covered exercise/tax liability with 13,909 shares, decreasing direct ownership by 0.86% to 1,599,154 units (SEC Form 4) to cover withholding tax
- President & CIO Sukhatme Mayukh sold $12,360,813 worth of shares (335,174 units at $36.88) and exercised 335,174 shares at a strike of $3.85 (SEC Form 4)
- President & CIO Sukhatme Mayukh exercised 664,826 shares at a strike of $3.85 and sold $24,160,402 worth of shares (664,826 units at $36.34) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.